Effects of water stably-enriched with oxygen as a novel method of tissue oxygenation on mitochondrial function, and as adjuvant therapy for type 2 diabetes in a randomized placebo-controlled trial.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
31
07
2020
accepted:
07
06
2021
entrez:
14
7
2021
pubmed:
15
7
2021
medline:
11
11
2021
Statut:
epublish
Résumé
Diabetes mellitus is associated with inadequate delivery of oxygen to tissues. Cellular hypoxia is associated with mitochondrial dysfunction which increases oxidative stress and hyperglycaemia. Hyperbaric oxygenation therapy, which was shown to improve insulin sensitivity, is impractical for regular use. We evaluated the effects of water which is stably-enriched with oxygen (ELO water) to increase arterial blood oxygen levels, on mitochondrial function in the presence of normal- or high-glucose environments, and as glucose-lowering therapy in humans. We compared arterial blood oxygen levels in Sprague-Dawley rats after 7 days of ad libitum ELO or tap water consumption. Mitochondrial stress testing, and flow cytometry analysis of mitochondrial mass and membrane potential, were performed on human HepG2 cells cultured in four Dulbecco's Modified Eagle Medium media, made with ELO water or regular (control) water, at normal (5.5 mM) or high (25 mM) glucose concentrations. We also randomized 150 adults with type 2 diabetes (mean age 53 years, glycated haemoglobin HbA1c 8.9% [74 mmol/mol], average duration of diabetes 12 years) to drink 1.5 litres daily of bottled ELO water or drinking water. ELO water raised arterial oxygen tension pO2 significantly (335 ± 26 vs. 188 ± 18 mmHg, p = 0.006) compared with tap water. In cells cultured in control water, mitochondrial mass and membrane potential were both significantly lower at 25 mM glucose compared with 5.5 mM glucose; in contrast, mitochondrial mass and membrane potential did not differ significantly at normal or high glucose concentrations in cells cultured in ELO water. The high-glucose environment induced a greater mitochondrial proton leak in cells cultured in ELO water compared to cells cultured in control medium at similar glucose concentration. In type 2 diabetic adults, HbA1c decreased significantly (p = 0.002) by 0.3 ± 0.7% (4 ± 8 mmol/mol), with ELO water after 12 weeks of treatment but was unchanged with placebo. ELO water raises arterial blood oxygen levels, appears to have a protective effect on hyperglycaemia-induced reduction in mitochondrial mass and mitochondrial dysfunction, and may be effective adjuvant therapy for type 2 diabetes.
Sections du résumé
BACKGROUND
Diabetes mellitus is associated with inadequate delivery of oxygen to tissues. Cellular hypoxia is associated with mitochondrial dysfunction which increases oxidative stress and hyperglycaemia. Hyperbaric oxygenation therapy, which was shown to improve insulin sensitivity, is impractical for regular use. We evaluated the effects of water which is stably-enriched with oxygen (ELO water) to increase arterial blood oxygen levels, on mitochondrial function in the presence of normal- or high-glucose environments, and as glucose-lowering therapy in humans.
METHODS
We compared arterial blood oxygen levels in Sprague-Dawley rats after 7 days of ad libitum ELO or tap water consumption. Mitochondrial stress testing, and flow cytometry analysis of mitochondrial mass and membrane potential, were performed on human HepG2 cells cultured in four Dulbecco's Modified Eagle Medium media, made with ELO water or regular (control) water, at normal (5.5 mM) or high (25 mM) glucose concentrations. We also randomized 150 adults with type 2 diabetes (mean age 53 years, glycated haemoglobin HbA1c 8.9% [74 mmol/mol], average duration of diabetes 12 years) to drink 1.5 litres daily of bottled ELO water or drinking water.
RESULTS
ELO water raised arterial oxygen tension pO2 significantly (335 ± 26 vs. 188 ± 18 mmHg, p = 0.006) compared with tap water. In cells cultured in control water, mitochondrial mass and membrane potential were both significantly lower at 25 mM glucose compared with 5.5 mM glucose; in contrast, mitochondrial mass and membrane potential did not differ significantly at normal or high glucose concentrations in cells cultured in ELO water. The high-glucose environment induced a greater mitochondrial proton leak in cells cultured in ELO water compared to cells cultured in control medium at similar glucose concentration. In type 2 diabetic adults, HbA1c decreased significantly (p = 0.002) by 0.3 ± 0.7% (4 ± 8 mmol/mol), with ELO water after 12 weeks of treatment but was unchanged with placebo.
CONCLUSIONS
ELO water raises arterial blood oxygen levels, appears to have a protective effect on hyperglycaemia-induced reduction in mitochondrial mass and mitochondrial dysfunction, and may be effective adjuvant therapy for type 2 diabetes.
Identifiants
pubmed: 34260650
doi: 10.1371/journal.pone.0254619
pii: PONE-D-20-22349
pmc: PMC8279347
doi:
Substances chimiques
Glycated Hemoglobin A
0
Hypoglycemic Agents
0
Insulin
0
Water
059QF0KO0R
Oxygen
S88TT14065
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0254619Déclaration de conflit d'intérêts
Sponsorship of this study by Elomart Pte Ltd does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.
Références
Genes Dev. 2013 Dec 1;27(23):2563-75
pubmed: 24298056
PLoS One. 2014 Mar 25;9(3):e92458
pubmed: 24667212
Diabetologia. 2015 Dec;58(12):2861-6
pubmed: 26404066
Drug Discov Today. 2008 Mar;13(5-6):268-74
pubmed: 18342804
Biochim Biophys Acta. 2010 Jun-Jul;1797(6-7):1171-7
pubmed: 20153717
Diabetes. 2012 Aug;61(8):2093-104
pubmed: 22698920
Fed Proc. 1979 Oct;38(11):2484-8
pubmed: 39792
J Nutr Sci. 2017 Sep 4;6:e47
pubmed: 29152251
Diabetologia. 2007 Jan;50(1):113-20
pubmed: 17093944
Sci Rep. 2017 Jan 12;7:40411
pubmed: 28079178
J Biol Chem. 2011 Apr 8;286(14):12524-32
pubmed: 21296882
Diabetes. 2013 Jun;62(6):1833-42
pubmed: 23328129
Anesth Analg. 1996 Mar;82(3):587-92
pubmed: 8623966
J Clin Endocrinol Metab. 2003 May;88(5):2055-60
pubmed: 12727954
PLoS One. 2016 Jul 06;11(7):e0158619
pubmed: 27383386
Diabetes Care. 2011 Dec;34(12):2551-4
pubmed: 21994426
Diabet Med. 2012 Aug;29(8):986-9
pubmed: 22269009
Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2653-8
pubmed: 16477035
Antioxid Redox Signal. 2017 Apr 1;26(10):501-518
pubmed: 27225690
Methods Mol Biol. 2015;1250:53-76
pubmed: 26272134
MethodsX. 2020 May 28;7:100938
pubmed: 32551241
Diabetes Care. 2019 Dec;42(12):2181-2189
pubmed: 31582428
Diabetologia. 2014 Aug;57(8):1635-44
pubmed: 24865615
Toxicol In Vitro. 2015 Jun;29(4):732-40
pubmed: 25746382
Biosci Biotechnol Biochem. 2014;78(5):843-50
pubmed: 25035988
Diabetes. 2013 Jun;62(6):1826-8
pubmed: 23704527
Diabetes Obes Metab. 2015 Apr;17(4):371-8
pubmed: 25523815
J Orthop Res. 2018 Sep;36(9):2476-2483
pubmed: 29663489
Toxicol Appl Pharmacol. 2007 Dec 1;225(2):214-20
pubmed: 17761203
Diabetes Obes Metab. 2017 Jan;19(1):125-132
pubmed: 27748014
Clin Chim Acta. 2013 Mar 15;418:63-71
pubmed: 23318564
Rev Endocr Metab Disord. 2013 Mar;14(1):77-86
pubmed: 23299658
Air Med J. 2008 Mar-Apr;27(2):86-90
pubmed: 18328973
Diabetes Care. 2016 Nov;39(11):2080-2088
pubmed: 27926891
Diabetes. 2009 Jan;58(1):95-103
pubmed: 18984735
Biochem J. 2011 Apr 15;435(2):297-312
pubmed: 21726199
Cell. 2014 Jun 5;157(6):1339-1352
pubmed: 24906151
Diabetes. 2016 Jun;65(6):1472-80
pubmed: 27222391
Diabetes Obes Metab. 2018 Sep;20(9):2286-2290
pubmed: 29687584
PLoS One. 2012;7(1):e29807
pubmed: 22235342
Kidney Int. 1983 Dec;24(6):795-9
pubmed: 6674673
Nutr Res. 2017 Jul;43:25-32
pubmed: 28739050
Br J Nutr. 2016 Nov 10;:1-11
pubmed: 27831459
Diabetologia. 1989 Apr;32(4):231-5
pubmed: 2759361
J Endocrinol. 2018 Feb;236(2):R109-R143
pubmed: 29203573